Esrar kullanımı sırasında başlayan ve N, N-Dimetiltriptamin (DMT) kullanımı ile psikotik özellikler eklenen duygudurum bozukluğu: Bir olgu sunumu
N, N-dimetiltriptamin (DMT), liserjik asit dietilamid (LSD) benzeri serotonin agonisti bir hallüsinojendir. Sentetik olarak üretilmesinin yanı sıra, özellikle Güney Amerika’da yetişen pek çok bitkiden elde edilebilmektedir. Evrenle bütünlük ve sonsuzluk hissi gibi etkileri bulunan ve Güney Amerika yerlilerince geleneksel olarak şaman ayinlerinde de kullanılan “ayahuasca” isimli içeceğin içeriğinde de saptanan maddenin Türkiye’de kullanımına dair veri bulunmamaktadır. Bu makalede, 3 yıllık esrar kullanımı sonrasında ortaya çıkan bir hipomanik dönem içerisindeyken, DMT kullanımı ile psikotik özelliklerin eklenmesi sonucunda, klinik tablonun ani ve dramatik biçimde değişmesi ile karakterize bir olgu sunulmuştur.
A mood disorder episode with an onset under chronic cannabis consumption and accompanied with psychotic features immediately after N, N-Dimethyltryptamine (DMT) use: A case report
N, N-dimethyltryptamine (DMT) is a serotonin agonist hallucinogen, similar to lysergic acid diethylamide (LSD). Syntetic production of DMT as well as extraction from several plants of South American flora is possible. DMT migth induce feelings of unity with the cosmos and experiences of eternity, and it is a natural content of a traditional South American beverage –ayahuasca- which is consumed at shamanistic rituals. There is not any data on the abuse of DMT in Turkey to date. We here present a case characterised by sudden and dramatic changes in the clinical features of a hypomanic episode induced after three years of cannabis use, immediately after consuming DMT due to the addition of psychotic features.
___
- 1. Manske RHF. A synthesis of the methyltryptamines and some derivatives. Can J Res 1931; 5:592-600.
- 2. Gable RS. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 2007; 102:24-34.
- 3. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther 2004; 102:111-129.
- 4. Thompson MA, Moon E, Kim UJ, Xu J, Siciliano MJ, Weinshilboum RM. Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization. Genomics 1999; 61:285-297.
- 5. Ciprian-Ollivier J, Cetkovich-Bakmas MG. Altered consciousness states and endogenous psychoses: a common molecular pathway? Schizophr Res 1997; 28:257-265.
- 6. Freye E, Levy JV (editors). Dimethyltryptamine (DMT) a Psychedelic. In: Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs. Newyork: Springer, 2009, 219-221.
- 7. Freebaze DMT. DMT and Ayahuasca. Drugs Forum. http://www.drugs-forum.com/forum/showthread.php?t=9127.
- 8. Richardson TH. Cannabis use and mental health: A review of recent epidemiological research. International Journal of Pharmacology 2010; 6:796-807.
- 9. Doğanavşargil GÖ, Sertöz ÖÖ, Coşkunol H, Şen G. EÜTF Psikiyatri Anabilim Dalı Bağımlılık Tedavi Biriminin Hasta Verilerinin On Yıllık Geriye Dönük Olarak İncelemesi: Madde Kullanan Hastaların Sosyodemografik Özellikleri. Bağımlılık Dergisi 2004; 5:115-120.
- 10. Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use and expression of mania in the general population. J Affect Disord 2006; 95:103-110.
- 11. Daumann J, Heekeren K, Neukirch A, Thiel CM, Möller- Hartmann W, Gouzoulis-Mayfrank E. Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology 2008; 200:573-583.
- 12. Carter CS, Robertson LC, Chaderjian MR, O’Shora-Celaya L, Nordahl TE. Attentional asymmetry in schizophrenia: the role of illness subtype and symptomatology. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:661-683.
- 13. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 2005; 38:301- 311.
- 14. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20:389-409.
- 15. Amerikan Psikiyatri Birliği. Ruhsal Bozuklukların Tanısal ve Sayımsal Elkitabı Yeniden Gözden Geçirilmiş Tam Metin, 4. baskı (DSM–IV–TR). Köroğlu E (Çeviri ed.) Ankara: Hekimler Yayın Birliği, 2007, 267-418.
- 16. DMT. Hallucinogens Part 2. Ask Pat. http://askpat.colostate.edu/ ViewHotTopic.aspx?HotTopicID=38#5.
- 17. Richardson WH, Slone CM, Michels JE. Herbal drugs of abuse: an emerging problem. Emerg Med Clin North Am 2007;25:435-457.
- 18. Jacob MS, Presti DE. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine. Med Hypotheses 2005; 64:930-937.
- 19. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther 2004; 102:111-129.
- 20. bilgiedinme@egm.gov.tr adresinden kişisel iletişim.